Dr. Jonathon Campbell
Assistant Professor, Department of Medicine, Division of Experimental Medicine
My research centres on generating evidence to inform the design and implementation of novel tuberculosis prevention and care strategies that maximize public health impact, while minimizing health system and patient costs. My primary aim is to optimize identification and treatment of tuberculosis infection to prevent progression to tuberculosis disease, with a particular focus on prevention among persons born outside of Canada—a population disproportionately impacted by tuberculosis. I also have an interest in improving the treatment of drug-resistant tuberculosis and efficiency of active tuberculosis case-finding activities in high-burden areas. Beyond tuberculosis, I have an interest in testing strategies for SARS-CoV-2 and methods to evaluate public health emergency preparedness and response, with a view to identify priority areas for investment.
- Cost-effectiveness of universal and targeted tuberculosis infection screening and treatment prior to initiation of tumour-necrosis factor alpha inhibitors at the Montreal Chest Institute.
- Identification of population groups with favorable risk-benefit profiles for tuberculosis preventive treatment using health administrative data in British Columbia.
- Improving the quality and utility of tuberculosis surveillance data to monitor and inform tuberculosis elimination in Canada.
- Campbell JR, Winters N, Menzies D. Absolute risk of tuberculosis among untreated populations with a positive tuberculin skin test or interferon-gamma release assay result: systematic review and meta-analysis. BMJ. 2020 Mar 10;368:m549. PMID: 32156698.
- Campbell JR, Trajman A, Cook VJ, Johnston JC, Adjobimey M, Ruslami R, Eisenbeis L, Fregonese F, Valiquette C, Benedetti A, Menzies D. Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis of two randomised controlled trials. Lancet Infect Dis. 2020 Mar;20(3):318-329. PMID: 31866327.
- Campbell JR, Nsengiyumva P, Chiang LY, Jamieson F, Khadawardi H, Mah HK, Oxlade O, Rasberry H, Rea E, Romanowski K, Sabur NF, Sander B, Uppal A, Johnston JC, Schwartzman K, Brode SK. Costs of Tuberculosis at 3 Treatment Centers, Canada, 2010-2016. Emerg Infect Dis. 2022 Sep;28(9):1814-1823. PMID: 35997366.
- Campbell JR, Dion C, Uppal A, Yansouni CP, Menzies D. Systematic on-site testing for SARS-CoV-2 infection among asymptomatic essential workers in Montréal, Canada: a prospective observational and cost-assessment study. CMAJ Open. 2022 Apr-Jun;10(2):E409-E419. PMID: 35537749.
- Campbell JR, Faust L, Paulsen C, Heffernan C. The State of Tuberculosis Surveillance in Canada. Can J Pub Health. 2023; online ahead of print. PMID 37014575
- Bastos ML, Perlman-Arrow S, Menzies D, Campbell JR. The Sensitivity and Costs of Testing for SARS-CoV-2 Infection With Saliva Versus Nasopharyngeal Swabs : A Systematic Review and Meta-analysis. Ann Intern Med. 2021 Apr;174(4):501-510. PMID: 33428446.